Open

Coming up

Don't miss

Replay


LATEST SHOWS

IN THE PAPERS

'iVIOLATED'

Read more

BUSINESS DAILY

France's Iliad considers fresh offer for T-Mobile

Read more

IN THE PAPERS

Back to school!

Read more

WEB NEWS

USA: Thousands pay tribute to Michael Brown

Read more

MEDIAWATCH

Is Carla Bruni against a political comeback for Sarkozy?

Read more

DEBATE

Pakistan Protests: Democracy put to the test (part 2)

Read more

DEBATE

Pakistan Protests: Democracy put to the test

Read more

ENCORE!

The French Maestro of Soul

Read more

FOCUS

US tobacco giants want lion's share of e-cigarette business

Read more

  • NATO plans new 'spearhead' force to counter Russia

    Read more

  • Arab media strike back at IS Islamists – with cartoons

    Read more

  • US military targets Somalia's al Shabaab Islamist group

    Read more

  • Boko Haram Islamists seize northeast Nigerian town

    Read more

  • Monaco’s Falcao leaves Ligue 1 for Man Utd

    Read more

  • UN backs Iraqi request for inquiry into IS militant crimes

    Read more

  • French education ministry picture sparks racist abuse

    Read more

  • Obama calls for higher wages amid 'revving' US economy

    Read more

  • Video: Ukraine’s children return to school as fighting rages on

    Read more

  • Americans detained in North Korea call for US help

    Read more

  • US urges Israel to reverse West Bank land seizure

    Read more

  • Lesotho PM calls for regional peacekeeping force after ‘coup’

    Read more

  • Ukrainian forces retreat from Luhansk airport after clashes

    Read more

  • Teddy Riner, France’s unstoppable judo champion

    Read more

  • Death toll rises in Paris apartment building blast

    Read more

  • Iraqi forces free Amerli in biggest victory over IS militants since June

    Read more

  • Anti-govt protesters briefly seize Pakistan's state TV

    Read more

SCIENCE

Teenage girl dies after receiving cervical cancer vaccine

Text by NEWS WIRES

Latest update : 2009-09-29

A 14-year-old British girl died on Monday shortly after receiving a cervical cancer vaccine made by GlaxoSmithKline. A link between the death and the drug has not yet been established, health officials said on Monday.

REUTERS - A teenage British girl died after receiving a cervical cancer vaccine made by GlaxoSmithKline, but a link between the death and the drug has not yet been established, health officials said on Monday.

The 14-year-old fell ill after she was given the Cervarix vaccination against the sexually transmitted human papillomavirus (HPV) at her school in Coventry, central England, as part of a national immunization program. She later died in a hospital.

"The incident happened shortly after the girl had received her HPV vaccine in the school," Dr. Caron Grainger, joint director for Public Health for NHS (National Health Service) Coventry and Coventry City Council, said in a statement.

"No link can be made between the death and the vaccine until all the facts are known and a post mortem takes place," Grainger said. "We are conducting an urgent and full investigation into the events surrounding this tragedy."

Glaxo said it was working with the Department of Health and MHRA (Medicines and Healthcare products Regulatory Agency) to better understand the case.

"At this stage the exact cause of this tragic death is unknown," Glaxo medical director Dr. Pim Kon said in a statement.

"As a precautionary measure, the batch of vaccine involved has been quarantined until the situation is fully understood," Kon added.

News of the death comes on the eve of a possible decision by U.S. health regulators on whether to approve Cervarix for sale in the United States. However, the U.S. Food and Drug Administration often lets its expected action dates pass without a decision, or announces a delay.

A small number of other girls at the school reported mild symptoms such as dizziness and nausea but were not admitted to a hospital, health officials said.

GlaxoSmithKline, based in Brentford, Middlesex, said more than 1.4 million doses of Cervarix had been given as part of the national immunization program.

It said adverse reactions reported so far had related to signs and symptoms of recognized side effects, or were due to the injection and not the vaccine itself.

Cervarix is administered in three separate shots over six months.

Should it gain U.S. approval it would compete with Merck & Co's Gardasil, which has been in the market in the United States since 2006 and had sales of $268 million in the second quarter.

Date created : 2009-09-29

COMMENT(S)